Qrons Inc., a biotechnology company focused on developing treatments and technologies to combat neuronal and infectious diseases, has recently announced that Professor Shiri Navon-Venezia will join its Scientific Advisory Board. Professor Navon-Venezia, a renowned expert in microbiology and head of the Bacterial Pathogens & Antibiotic Resistance Lab at Ariel University, brings a wealth of expertise in antibiotic research and development.
Antimicrobial resistance remains one of the most pressing global public health threats, with millions of people worldwide falling victim to antibiotic-resistant infections each year. Qrons Inc. aims to address this critical issue by studying the therapeutic potential of Tellurium-based compounds to combat antibiotic resistance in bacterial infections, including Sepsis.
Sepsis, a life-threatening condition associated with high mortality rates, poses a significant challenge in intensive care units. The CDC reports that over 1.7 million people in the U.S. develop sepsis annually, with approximately 350,000 patients dying or being discharged to hospice care. Shockingly, sepsis is identified as a contributing factor in one out of every three hospital deaths.
“We are delighted to welcome Professor Navon-Venezia to Qrons’ Scientific Advisory Board,” said Jonah Meer, CEO of Qrons. “Her extensive background in antibiotic research will play a vital role in shaping our research program and propelling our efforts to develop innovative solutions that address antibiotic resistance in bacterial infections, particularly Sepsis.”
By leveraging strategic collaborations, Qrons aims to tap into the expertise of leading universities, companies, and scientists in the fields of stem cells, antibiotic-resistant drug development, and tissue engineering. These collaborations will accelerate the deployment of groundbreaking therapies and technologies to combat neuronal and infectious diseases.
In conclusion, Qrons Inc.’s addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board signals the company’s commitment to combating antibiotic resistance infections. With Professor Navon-Venezia’s invaluable expertise, Qrons aims to pave the way for novel approaches and breakthrough treatments in the fight against antimicrobial resistance.
What is antimicrobial resistance?
Antimicrobial resistance refers to the ability of microorganisms, such as bacteria, viruses, parasites, and fungi, to resist the effects of medications that were previously effective in treating infections. This resistance makes it challenging to treat common diseases and infections, leading to prolonged illnesses, increased healthcare costs, and higher mortality rates.
What is Sepsis?
Sepsis is a life-threatening condition triggered by an infection that can rapidly progress and cause organ failure and death. It occurs when the body’s response to an infection spirals out of control, leading to widespread inflammation and injury. Prompt medical attention and treatment are crucial for improving sepsis outcomes.
How is Qrons Inc. addressing antibiotic resistance?
Qrons Inc. is dedicated to developing innovative products, treatments, and technologies to combat neuronal and infectious diseases, with a particular focus on antibiotic-resistant bacteria. The company aims to explore the therapeutic potential of Tellurium-based compounds in tackling antibiotic resistance and enhancing the efficacy of treatment for bacterial infections, including Sepsis.
What collaborations does Qrons Inc. seek?
Qrons Inc. seeks strategic arrangements and collaborations with universities, companies, and scientists at the forefront of stem cell research, antibiotic-resistant drug development, and tissue engineering. By combining unique knowledge and intellectual properties, Qrons aims to accelerate the development and deployment of groundbreaking therapies and technologies.